Tuesday 27 March, 12-1pm, Seminar Room 1, TRFPresented by Dr Kim O'Sullivan, Research Fellow, Centre for Inflammatory Diseases
Myeloperoxidase anti-neutrophil
cytoplasmic antibody associated vasculitis (MPO-AAV) is a major cause of chronic
kidney disease. Current treatment for ANCA-vasculitis consists of non-targeted
immunosuppression which is toxic and contributes to morbidity and mortality
rates. There is an unmet need for the development of therapeutics which will
target pro inflammatory immune responses without causing adverse effects. This
presentation will explore the role of extracellular DNA as a contributing
factor to ANCA vasculitis and the use of DNase I as a therapeutic in models of
experimental anti-myeloperoxidase ANCA glomerulonephritis.
Kim O’Sullivan has recently
completed her PhD within the Autoimmune Kidney Disease and Vasculitis Research
Group with Prof. Stephen Holdsworth and Prof. Richard Kitching at the Centre
for Inflammatory Diseases. Kim’s research is focused on trying to find new
novel targets and biological interventions in human and experimental ANCA
associated vasculitis.
No comments:
Post a Comment